Evidence map›Paper›PMID 35344481›Full record

ArticleeLife2022

Tackling variants with antibodies.

Elizabeth H Aitken, Stephen J Rogerson

Open access · goldAbstract readEditorialComment
PubMed Full text at PMC Publisher
In one paragraph

Article in eLife, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Elizabeth H AitkenDepartment of Infectious Diseases, Department of Microbiology and Immunology, at the Doherty Institute, University of Melbourne, Melbourne, Australia.ORCID 0000-0002-2677-6208
Stephen J RogersonDepartment of Infectious Diseases, Department of Microbiology and Immunology, at the Doherty Institute, University of Melbourne, Melbourne, Australia.ORCID 0000-0003-4287-1982
The University of Melbourne · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibodies targeting the protein that causes placental malaria can recognise multiple variants of the protein, which may help guide the development of new vaccines to protect pregnant women from malaria.

Indexed as

MalariaMalaria, FalciparumPregnancy Complications, ParasiticAntibodies, ProtozoanFemaleHumansPlacentaPregnancyAntibodies, Protozoanblocking antibodyimmunologyinfectious diseaseinflammationmalariamicrobiologyP. falciparumPlacental malariapregnancyvaccineVAR2CSAvariant

Identifiers

PMID35344481
PMCPMC8959596
OpenAlexW4220795997

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.